CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,914,570 | -8.8% | 240,462 | +12.9% | 0.01% | -7.1% |
Q2 2023 | $11,962,031 | +25.9% | 213,075 | +1.5% | 0.01% | +27.3% |
Q1 2023 | $9,498,571 | +28.5% | 210,006 | +15.5% | 0.01% | +22.2% |
Q4 2022 | $7,391,268 | -0.6% | 181,827 | +57.7% | 0.01% | 0.0% |
Q3 2022 | $7,435,000 | +18.0% | 115,291 | +11.2% | 0.01% | +28.6% |
Q2 2022 | $6,299,000 | +213.4% | 103,661 | +223.7% | 0.01% | +250.0% |
Q1 2022 | $2,010,000 | -22.6% | 32,025 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $2,597,000 | -23.7% | 34,273 | +12.8% | 0.00% | -50.0% |
Q3 2021 | $3,402,000 | -7.5% | 30,397 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $3,679,000 | -3.8% | 30,397 | -3.2% | 0.00% | 0.0% |
Q1 2021 | $3,826,000 | -21.2% | 31,396 | -1.0% | 0.00% | -33.3% |
Q4 2020 | $4,855,000 | – | 31,708 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |